Key outcomes: Mean weight loss: 14.9% (vs 2.4% placebo) 86.4% of participants achieved 5% loss (vs 31.5% placebo) 50.5% achieved 15% loss (vs 4.9% placebo) SELECT (Lincoff et al., NEJM 2023) added the cardiovascular signature: in 17,604 non-diabetic adults with prior CV history, semaglutide 2.4 mg reduced MACE (CV death, MI, stroke) by 20% over 3 years
Not a weight loss program
Safety depends on formulation and oversight, which is why many patients prefer prescription treatments
Important safety considerations include a boxed warning for medullary thyroid carcinoma (MTC) risk with most GLP-1 medications, which are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Our quality assurance process emphasizes: Batch traceability Third-party laboratory testing where applicable Certificate of Analysis (COA) availability Consistent research-grade production standards These procedures help maintain the level of quality expected from professional research peptides used in scientific environments
They shape how clinicians initiate therapy, how insurers assess coverage, and how patients perceive the purpose of the medication